Opendata, web and dolomites

HepatoRiSK TERMINATED

A new tumor suppressor role for RSK2 in hepatocellular carcinoma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HepatoRiSK project word cloud

Explore the words cloud of the HepatoRiSK project. It provides you a very rough idea of what is the project "HepatoRiSK" about.

acute    co    samples    patient    assistant    cancer    therapies    responsibilities    models    cas9    cells    suppressor    inhibit    independent    ras    model    found    mutated    biochemical    nearly    professor    elucidate    inhibitor    fellowship    unexpectedly    genome    mechanisms    mutating    revealed    hypothesize    options    functionally    kinase    partly    activates    subject    genes    mutations    carcinoma    supervision    techniques    injection    stone    context    whereby    hampers    sequencing    combines    genetic    career    hydrodynamic    phenotypic    lab    kinases    vein    me    uncover    mortality    altogether    editing    performed    landscape    vitro    intervention    months    molecular    tumor    mechanistic    ranks    frequently    validated    reagents    genetics    dependent    crispr    mouse    poor    hcc    gene    formal    aberrations    hepatocellular    feed    rsk2    adult    mapped    host    mechanism    basis    erk    tail    acting    stepping    worldwide    back    mice    liver    potently    postdoc    function    raf    limited    treatment   

Project "HepatoRiSK" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 212˙194 €
 EC max contribution 212˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  0000-00-00

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 212˙194.00

Map

 Project objective

Hepatocellular carcinoma (HCC) ranks third in cancer mortality worldwide. In spite of this, effective treatment options are limited, partly due to a poor understanding of the molecular basis of HCC, which hampers development of targeted therapies. Recently, cancer genome sequencing mapped the landscape of genetic aberrations in HCC and unexpectedly revealed the kinase RSK2 as the most frequently mutated gene in the RAS-RAF-ERK pathway. I hypothesize that RSK2 is a tumor suppressor in HCC by acting as a feed-back inhibitor of the RAS-ERK pathway, since I find that RSK2 mutations are nearly all loss-of-function and that RSK2 loss potently activates ERK kinases in liver cells. The goal of this proposal is to functionally establish RSK2 as a novel and important tumor suppressor in HCC and identify the mechanism(s) whereby RSK2 may feed-back inhibit the RAS-ERK pathway to promote this cancer. This will be achieved through modelling RSK2 loss in liver cells in vitro and in mice. Among other approaches, I will model RSK2-dependent HCC development by mutating genes found co-mutated with RSK2 directly in the adult mouse liver via hydrodynamic tail vein injection of CRISPR/Cas9 reagents, which may cause HCC within months. I will subject cells and mouse models to mechanistic biochemical and phenotypic studies to elucidate the role and mechanism of RSK2 as a tumor suppressor in HCC. Key findings will be validated in HCC patient samples. The work will be performed in the context of my new role as assistant professor in the host lab, where I will be given formal supervision and management responsibilities. The work combines my postdoc experience in cancer genetics with my host´s beyond-state-of-the-art CRISPR/Cas9 genome editing techniques. Altogether, this fellowship has the potential to uncover new mechanisms for targeted intervention in HCC. Furthermore, it will be an important stepping stone for me towards an independent research career.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEPATORISK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEPATORISK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MY MITOCOMPLEX (2021)

Functional relevance of mitochondrial supercomplex assembly in myeloid cells

Read More  

CODer (2020)

The molecular basis and genetic control of local gene co-expression and its impact in human disease

Read More  

CYBERSECURITY (2018)

Cyber Security Behaviours

Read More